Developing Anti-Cancer Drug that Induces Immunogenic Cell Death with Dr. Joseph O’Donnell Phosplatin Therapeutics TRANSCRIPT

Empowered Patient Podcast

Dr. Joseph O'Donnell is the Chief Medical Officer at Phosplatin Therapeutics founded to develop a drug with platinum in it to kill cancer cells. Phosplatin is in clinical trials with PT-112 which is the first cancer therapy molecule that has a pyrophosphate on it and works by harnessing the immune system and causing immunogenic cell death.

Dr. Joe explains, "This drug is in this space that's really burgeoning called immuno-oncology, where we're using immune agents to stimulate the immune system to actually affect the cancer, to actually knock down the cancer. And this is one that has a different mechanism than some of the other agents and lots of potential to be used in combination to produce synergy with those other agents in this very exciting space."

"So, the checkpoint inhibitors are one group of drugs that seems to be interesting to combine with PT-112, and I suspect we'll see more of that in the future. But just PT-112 by itself, it has this effect called producing immunogenic cell death. That's a way in which a drug causes cancer cells to die by activating the immune system, the adaptive immune system, to actually attack the tumor and actually devour it. And so that's one of the properties that the PT-112 has."

@Phosplatin #Oncology #ImmunoOncology #Cancer #CancerTherapeutics #ICD #ImmunogenicCellDeath #Chemotherapy #CheckPointInhibitors #Innovation #NYBiotech

Phosplatin.com

Listen to the podcast here